Harry J. Leonhardt

2019 - Halozyme Therapeutics

In 2019, Harry J. Leonhardt earned a total compensation of $1.9M as Former Senior Vice President, General Counsel at Halozyme Therapeutics, a 2% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$217,152
Option Awards$625,007
Salary$464,000
Stock Awards$625,008
Other$16,536
Total$1,947,703

Leonhardt received $625K in stock awards, accounting for 32% of the total pay in 2019.

Leonhardt also received $217.2K in non-equity incentive plan, $625K in option awards, $464K in salary and $16.5K in other compensation.

Rankings

In 2019, Harry J. Leonhardt's compensation ranked 6,076th out of 13,971 executives tracked by ExecPay. In other words, Leonhardt earned more than 56.5% of executives.

ClassificationRankingPercentile
All
6,076
out of 13,971
57th
Division
Manufacturing
2,280
out of 5,695
60th
Major group
Chemicals And Allied Products
824
out of 2,194
62nd
Industry group
Drugs
696
out of 1,880
63rd
Industry
Biological Products, Except Diagnostic Substances
165
out of 389
58th

Pay ratio

Harry J. Leonhardt's Pay$1,947,703
Median Employee's Pay$238,096
Pay Ratio

8

to 1

In 2019, the annual total compensation of Harry J. Leonhardt was $1,947,703.

The annual total compensation of the median employee at Halozyme Therapeutics was $238,096.

The ratio of Harry J. Leonhardt's pay to the pay of median employee was therefore 8 to one.

Source: SEC filing on March 20, 2020.

Leonhardt's colleagues

We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2019.

2019

Helen Torley

Halozyme Therapeutics

Chief Executive Officer

2019

Alison Armour

Halozyme Therapeutics

Former Senior Vice President, Head of Research & Development

2019

Laurie Stelzer

Halozyme Therapeutics

Chief Financial Officer

2019

Benjamin Hickey

Halozyme Therapeutics

Former Senior Vice President, Chief Commercial Officer

News

You may also like